SETD2 and central nervous system cancer: Additionally, Fontebasso et al. demonstrated that HGGs with SETD2 mutations exhibited different DNA methylation signatures than that of H.3-G34R/V mutant gliomas [35], and Yadav et al. demonstrated that the deletion of the yeast homolog of SETD2 did not result in similar gene expression when compared to H3.3-G34R/V mutations [36].